| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 43.88% | Chardan Capital | → $2 | Upgrades | Neutral → Buy |
| 09/18/2023 | 29.5% | Citigroup | $2.1 → $1.8 | Maintains | Buy |
| 08/07/2023 | 259.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/04/2023 | 43.88% | Chardan Capital | → $2 | Reiterates | Neutral → Neutral |
| 05/17/2023 | 223.74% | Cantor Fitzgerald | $5 → $4.5 | Maintains | Overweight |
| 05/17/2023 | 331.65% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 05/17/2023 | 259.71% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 03/30/2023 | 331.65% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/30/2023 | 259.71% | HC Wainwright & Co. | $1.5 → $5 | Maintains | Buy |
| 12/23/2022 | 259.71% | Raymond James | $2 → $5 | Maintains | Outperform |
| 12/22/2022 | 259.71% | Cantor Fitzgerald | $0.8 → $5 | Upgrades | Neutral → Overweight |
| 08/15/2022 | 7.91% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 08/12/2022 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 08/12/2022 | 43.88% | Raymond James | → $2 | Upgrades | Market Perform → Outperform |
| 05/09/2022 | 43.88% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 05/06/2022 | 43.88% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 04/14/2022 | 79.86% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 04/14/2022 | 259.71% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 02/14/2022 | 475.54% | Chardan Capital | $18 → $8 | Maintains | Buy |
| 02/14/2022 | 475.54% | JMP Securities | $29 → $8 | Maintains | Market Outperform |
| 02/14/2022 | 187.77% | HC Wainwright & Co. | $20 → $4 | Maintains | Buy |
| 02/14/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 02/01/2022 | 1266.91% | Raymond James | → $19 | Initiates Coverage On | → Strong Buy |
| 08/09/2021 | 1194.96% | Chardan Capital | $20 → $18 | Maintains | Buy |
| 05/03/2021 | 1338.85% | Stifel | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 1338.85% | Chardan Capital | $25 → $20 | Maintains | Buy |
| 11/19/2019 | 2274.1% | Citigroup | $40 → $33 | Maintains | Buy |
| 11/14/2018 | 2777.7% | Cantor Fitzgerald | → $40 | Initiates Coverage On | → Overweight |
What is the target price for ProQR Therapeutics (PRQR)?
The latest price target for ProQR Therapeutics (NASDAQ: PRQR) was reported by Chardan Capital on November 8, 2023. The analyst firm set a price target for $2.00 expecting PRQR to rise to within 12 months (a possible 43.88% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ProQR Therapeutics (PRQR)?
The latest analyst rating for ProQR Therapeutics (NASDAQ: PRQR) was provided by Chardan Capital, and ProQR Therapeutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for ProQR Therapeutics (PRQR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProQR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProQR Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating ProQR Therapeutics (PRQR) correct?
While ratings are subjective and will change, the latest ProQR Therapeutics (PRQR) rating was a upgraded with a price target of $0.00 to $2.00. The current price ProQR Therapeutics (PRQR) is trading at is $1.39, which is within the analyst's predicted range.